APA

Abma E., De Spiegelaere W., Vanderperren K., Stock E., Van Brantegem L., Cornelis I., Daminet S., Ni Y., Vynck M., Verstraete G., Smets P. & de Rooster H. (20181127). A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers. : Veterinary and comparative oncology.

Chicago

Abma E, De Spiegelaere W, Vanderperren K, Stock E, Van Brantegem L, Cornelis I, Daminet S, Ni Y, Vynck M, Verstraete G, Smets P and de Rooster H. 20181127. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers. : Veterinary and comparative oncology.

Harvard

Abma E., De Spiegelaere W., Vanderperren K., Stock E., Van Brantegem L., Cornelis I., Daminet S., Ni Y., Vynck M., Verstraete G., Smets P. and de Rooster H. (20181127). A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers. : Veterinary and comparative oncology.

MLA

Abma E, De Spiegelaere W, Vanderperren K, Stock E, Van Brantegem L, Cornelis I, Daminet S, Ni Y, Vynck M, Verstraete G, Smets P and de Rooster H. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers. : Veterinary and comparative oncology. 20181127.